- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01814332
Analyzing Female Trauma Exposed Responses to a Medication (AFTER)
CRF Receptor Antagonist for PTSD and Related Sleep Disturbances in Women
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A growing body of literature suggests that stress-related disorders such as PTSD are associated with chronically increased activity of CNS circuits that utilize corticotropin-releasing factor (CRF), a neuropeptide involved in mediating the neuroendocrine, immune, autonomic, and behavioral responses to stress. CRF1 receptor antagonists exert significant dampening effects on this system, but have never been investigated in patients with PTSD. The investigators at Mount Sinai School of Medicine (MSSM) and the National Institute of Mental Health (NIMH) Intramural Research Program have conducted a Phase II proof-of-concept clinical trial of a neurokinin-1 antagonist provided by GlaxoSmithKline (GSK). In this investigation, we will conduct a 2-site (Emory and MSSM), 6-week, randomized, double-blind, placebo-controlled, parallel-arm, fixed dose trial evaluating the efficacy, safety, and tolerability of GSK561679 for 154 female adult outpatients with PTSD. The San Francisco Department of Veterans Affairs Medical Center (SFVAMC) was added as a site in July 2012. SFVAMC will enroll 40 female adult outpatients with PTSD.
We propose to investigate the efficacy of the highly specific CRF1 antagonist GSK561679 in PTSD in a placebo-controlled clinical trial. GSK561679 has not been approved by the Food and Drug Administration for the treatment of any condition. Furthermore, we propose to longitudinally investigate whether certain biological surrogate markers (neuroendocrine, neurophysiology, genotyping) are predictive of treatment response. If a patient is already taking medication for PTSD and has achieved therapeutic response, she will not be tapered off effective medication(s) to participate in this study, and will not be eligible for the study. Taper and discontinuation of medications in preparation for this study will only occur in those patients who are not responding to medication treatment for PTSD.
Preclinical and clinical literature also exists which implicates both hypothalamic and extra hypothalamic CRF in stress-related insomnia and the regulation of non-rapid eye movement delta sleep. There is preliminary evidence that blocking CRF signaling results in an immediate improvement in stress-related sleep disturbances. Disturbed sleep is the most prevalent symptom endorsed by PTSD patients. It is potentially debilitating in many domains of functioning, and it is an outcome that can be objectively and precisely measured with sleep EEG. Therefore, an exploratory aim of this study will be to investigate the impact of GSK561679 on objective measures of sleep continuity and quantitative sleep EEG using ambulatory polysomnography. All subjects enrolled at SFVAMC who meet inclusion and exclusion criteria for the study will be given the option of having their sleep monitored throughout the study
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
San Francisco, California, United States, 94121
- San Francisco VA Medical Center, San Francisco, CA
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Female between 18-65 years of age
- Able to provide consent and willing to participate in research
- PTSD duration of illness at least 3 months
- Negative Urine toxicology test
- Agrees to use protocol-defined effective birth control method
Exclusion Criteria:
- Subject is currently participating in another clinical trial in which she is or will be exposed to an investigational or non-investigational drug or device, or has done so within the preceding month for studies unrelated to PTSD, or 1 month for studies related to PTSD
- Subject has a documented history of hepato-biliary disease including a history of, or positive laboratory results for hepatitis
- Subject requires ongoing treatment with medications that are prohibited per protocol
- Subject has a stool positive for occult blood.
- Pregnancy or lactation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: GSK561679
GSK561679, oral administration, 350mg/day, 6 week administration
|
GSK561679, oral administration, 350mg/day, 6 week administration
Other Names:
|
Placebo Comparator: Placebo
Placebo compound treatment for comparison with IP
|
Placebo compound treatment for comparison with IP
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy, Measured by Change in the Clinician-Administered PTSD Scale (CAPS) Score
Time Frame: Baseline, 6 weeks
|
The CAPS is a semi-structured clinical interview providing a measure of the severity of PTSD symptoms.
A severity score is calculated by summing the frequency and intensity scores for each of the 17 DSM-IV criteria symptoms.
The severity of symptoms is rated on a scale from 0-4, where, 0 = Absent, 1 = Mild/subthreshold; 2 = Moderate/ threshold, 3 = Severe/markedly elevated and 4 = Extreme/ incapacitating.
Scores may range from 0 (no symptoms) to 136 (severe symptoms).
Change is the difference in scores between baseline and 6 weeks.
|
Baseline, 6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy, Measured by Change in the Montgomery-Asberg Depression Rating Scale (MADRS) Score
Time Frame: Baseline, Week 6
|
The MADRS is a ten-item clinician-administered questionnaire used to measure the severity of depressive symptoms in patients with depressive disorders.
Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6.
The overall score ranges from 0 to 60. Change is the difference in scores between baseline and 6 weeks.
|
Baseline, Week 6
|
Efficacy, Measured by Response Rate of at Least 50% Improvement in CAPS Score at the End of 6 Weeks as Compared to Baseline
Time Frame: Baseline, Week 6
|
The number of participants that showed at least a 50% reduction in CAPS scores from their baseline visit at the end of 6 weeks were measured as having a response to the treatment.
The CAPS is a semi-structured clinical interview providing a measure of the severity of PTSD symptoms.
A severity score is calculated by summing the frequency and intensity scores for each of the 17 DSM-IV criteria symptoms.
Scores may range from 0 (no symptoms) to 136 (severe symptoms).
|
Baseline, Week 6
|
Safety, Measured by the Number of Subjects That Experienced an Adverse Event
Time Frame: Baseline, Week 6
|
The occurrence of adverse events will be recorded at the end of 6 weeks.
|
Baseline, Week 6
|
Collaborators and Investigators
Investigators
- Principal Investigator: Thomas C. Neylan, MD, San Francisco VA Medical Center, San Francisco, CA
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 09S-NIMH-002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stress Disorders, Post-traumatic
-
University of California, Los AngelesDefense Advanced Research Projects Agency; Defense Group, Inc.CompletedPost-traumatic Stress Disorder | Post-Traumatic Stress Disorder, ChronicUnited States
-
Weill Medical College of Cornell UniversityCompletedPost-traumatic Stress Disorder | Complex Post-Traumatic Stress DisorderUnited States
-
Oregon Health and Science UniversityNational Center for Complementary and Integrative Health (NCCIH); Oregon Clinical...CompletedPost-Traumatic Stress DisordersUnited States
-
US Department of Veterans AffairsEmory UniversityWithdrawnPost-Traumatic Stress Disorders
-
University of KonstanzGerman Research Foundation; NGO vivo e.V.; GTZ-German Technical Cooperation,... and other collaboratorsCompletedPost-Traumatic Stress DisordersSri Lanka
-
University Hospital, ToulouseCompletedPost-traumatic StressFrance
-
University of California, Los AngelesRecruitingPost-traumatic Stress Disorder | Post-Traumatic Stress Disorder in ChildrenUnited States
-
University of UtahEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedPost-Traumatic Stress Disorder in Children | Post-Traumatic Stress Disorder in AdolescenceUnited States
-
University Hospital, LilleNot yet recruiting
-
Steinn SteingrimssonRecruiting
Clinical Trials on GSK561679
-
GlaxoSmithKlineCompletedDepressive Disorder, MajorUnited States
-
Emory UniversityIcahn School of Medicine at Mount SinaiCompletedStress Disorders, Post-TraumaticUnited States
-
GlaxoSmithKlineWithdrawn
-
GlaxoSmithKlineCompletedHealthy SubjectsUnited States
-
National Institute on Alcohol Abuse and Alcoholism...Completed
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedDepressive Disorder and Anxiety DisordersUnited Kingdom